Credits: Canva
As fertility issues continue to rise among women, doctors are sounding the alarm on an often-overlooked set of culprits — smoking, alcohol, and vaping. Once seen as lifestyle choices, these habits are now being recognised as major threats to reproductive health, increasing the risk of miscarriages, hormonal disruptions, and long-term fertility complications.
As reported in Business Standard, according to Dr Anuja Thomas, consultant obstetrician and gynaecologist at Motherhood Hospitals, Kharghar, lifestyle vices like smoking, drinking, and vaping are silently damaging reproductive health in both women and men. “Many people assume that pausing or reducing these habits only while trying to conceive is enough. But that’s a dangerous misconception,” she said.
These substances, she explained, disrupt hormonal balance, interfere with menstrual cycles, and can reduce fertility. “They damage reproductive organs and even the health of future offspring. It’s essential to quit these habits completely, not temporarily,” she added.
Dr Manju Gupta, senior consultant at Motherhood Hospitals, Noida, highlighted that smoking impacts male and female fertility alike. In women, it accelerates the loss of eggs, damages the fallopian tubes, and raises the risk of ectopic pregnancy and miscarriage. It also affects the uterus, making it harder for a fertilised egg to implant.
Men are not spared either. “Smoking reduces sperm count and quality, and causes DNA damage. This can contribute to miscarriages and even birth defects,” she explained. Passive smoking, she warned, is equally harmful and should not be overlooked.
While vaping is often perceived as a safer option, doctors caution otherwise. Dr Neha Tripathi, fertility specialist at Nova IVF Fertility, Indirapuram, Delhi NCR, warned that vaping contains harmful chemicals that can damage the uterine lining and affect egg development.
“Smoking harms fallopian tubes, alcohol interferes with ovulation, and vaping leads to hormonal disruptions. These collectively make it harder for women to conceive,” she said. In men, these substances can lower testosterone levels and damage sperm DNA.
She advised that women who are planning a pregnancy — or even thinking about it in the future — should completely quit these habits. “A healthy diet, regular exercise, and early intervention to quit these vices are critical for protecting fertility,” she added.
The risks don’t end at fertility. Dr Gaurav Jaswal, consultant in radiation oncology at TGH Onco Life Cancer Centre, Talegaon, said that long-term use of tobacco, alcohol, and vaping products can also increase cancer risk in women.
“These substances weaken the immune system, damage DNA, and cause chronic inflammation. Over time, they raise the risk of breast, cervical, oral, and lung cancers,” he said. Dr Jaswal stressed the importance of making informed decisions and seeking expert help to quit these habits as early as possible.
Doctors across specialties agree: there is no safe amount or “right time” to consume tobacco, alcohol, or vape products if one is trying to conceive. The best course of action is to qui
Credits: Canva
A retracted eardrum, also called tympanic membrane atelectasis, is a condition where the eardrum gets pulled inward toward the middle ear. Normally, the eardrum (or tympanic membrane) acts as a boundary between the outer and middle ear, transmitting sound vibrations to tiny bones that help us hear. But when it collapses inward, that delicate process can be disrupted.
The condition is often silent at first, meaning people may not realize they have it. But in some cases, it can escalate, causing discomfort or even permanent hearing damage.
In most cases, a retracted eardrum doesn’t cause any noticeable symptoms. But when the retraction becomes severe enough to affect structures inside the ear, individuals may experience:
If left untreated, a chronic retracted eardrum can lead to permanent hearing loss.
The most common cause of a retracted eardrum is Eustachian tube dysfunction. These narrow tubes connect the middle ear to the back of the nose and help regulate ear pressure.
When they don’t work properly, pressure inside the ear drops, effectively pulling the eardrum inward.
Some common triggers include:
Upper respiratory infections, such as the common cold
Diagnosis typically begins with a discussion about symptoms and any recent infections. A doctor will then use an otoscope, a tool with a light, to look into the ear canal. This allows them to visually confirm if the eardrum is abnormally positioned or collapsed.
Not all retracted eardrums require immediate treatment. In mild cases, doctors often recommend a “watch and wait” approach, as pressure may normalize naturally over a few months.
For more advanced cases, several interventions are possible:
Decongestants or nasal steroids: These can improve airflow in the ear and relieve pressure.
The Valsalva maneuver: This self-administered technique involves closing your mouth, pinching your nose, and gently blowing as if trying to pop your ears. It should be performed under medical guidance.
If the condition begins to affect hearing or causes persistent pain, surgical options may be considered.
Two common surgical treatments are:
Tube Insertion (Myringotomy):
Often used in children with recurring ear infections, this procedure involves placing small tubes into the eardrum to help ventilate the middle ear.
Tympanoplasty:
In more severe cases, part of the damaged eardrum may be removed and replaced with cartilage from the outer ear. This stiffens the eardrum, preventing future collapses.
The outlook largely depends on the severity. Minor retractions usually resolve without intervention and don’t cause long-term damage. However, more serious cases, especially those that persist or press against ear bones, may result in hearing loss and need medical or surgical correction.
Experts recommend seeking medical attention if you notice ear discomfort, hearing changes, or frequent infections. Early diagnosis can prevent long-term issues and protect one of your most important senses, your hearing.
Credits: Canva
In a surprising discovery that bridges the gap between creepy crawlies and cutting-edge neuroscience, researchers at Virginia Tech have identified unique compounds in millipede secretions that could pave the way for future treatments for pain and neurological diseases like Parkinson’s, depression, and schizophrenia.
Led by chemist Emily Meyers, the research team uncovered naturally occurring alkaloids in the defensive secretions of the Andrognathus corticarius, a species known colloquially as the Hokie millipede. The millipede, which lives under decomposing leaves and branches on the university’s Blacksburg campus, produces a chemical cocktail that not only deters predators but may influence neuroreceptors in the brain.
“These compounds are quite complex, so they’re going to take some time to synthesize in the lab,” said Meyers, who specializes in studying underexplored ecological sources for potential new drugs.
The compounds, dubbed andrognathanols and andrognathines by Meyers’ team, belong to a class of complex alkaloids. They were discovered after researchers collected several millipedes from wooded areas on campus and analyzed the contents of their defensive glands using a suite of chemical tools.
The results were striking: some of these secretions had a disorienting effect on ants, one of the millipede’s presumed predators. But that’s not all, several of the compounds were found to interact with a neuroreceptor known as Sigma-1. This receptor has been linked to multiple brain disorders, including schizophrenia, depression, Lou Gehrig’s disease (ALS), and Parkinson’s disease.
In addition to warding off predators, the researchers discovered that the compounds may also serve a social function, possibly helping millipedes signal their location to family members in leaf-littered environments.
This study, recently published in the Journal of the American Chemical Society, is not Meyers’ first foray into studying arthropod chemistry. She has been collaborating with entomologist Paul Marek, and together, they have previously suggested that the family of alkaloids found in millipede secretions could have significant therapeutic potential.
“Millipedes have been around for hundreds of millions of years. They’ve developed these intricate chemical defense systems, and we’re only beginning to understand their value,” said Meyers.
While the compounds show promise, the next hurdle is a familiar one in drug discovery: scalability. The compounds exist in trace amounts in the wild, and researchers need larger quantities for in-depth testing and potential pharmaceutical development.
The team is now exploring partnerships with laboratories that can synthesize the compounds in bulk, which would allow for further testing on their biological activity and medicinal properties. Meyers emphasized that while the research is still in its early stages, the potential applications are broad, from pain management to novel treatments for complex neurological conditions.
“Nature has always been a wellspring of inspiration for medicine,” said Meyers. “And sometimes, the most powerful solutions come from the smallest and most unexpected creatures, like a tiny millipede under a log.”
With this groundbreaking discovery, scientists are reminded once again that the natural world may hold secrets that, once unlocked, could transform human health in unimaginable ways.
(Credit-Canva)
Cancers are unpredictable and can be either containable or completely wreck your health. To make cancer treatments and research better, healthcare professionals use stages and characteristics, making it easier for us to categorize and identify how far along the disease is. However, recent research has been questioning our stance on this particular cancer, saying it could be worse than what we had believed.
A recent study has found that a specific type of prostate tumor, called Grade Group one (GG1), might not be as harmless as once believed. While many doctors consider these tumors to be at low risk of spreading and recommend monitoring them, the new research suggests the true risk might be higher. In fact, the study indicates that up to 30% of these cases could be more serious than doctors think, and a closer look could save lives.
For years, men diagnosed with a GG1 tumor were often told to skip immediate treatment and instead undergo "active surveillance." This means they were regularly checked with blood tests and follow-up biopsies to see if the tumor was growing.
However, researchers point out a key problem: a single biopsy might miss more aggressive cancer cells located in a different part of the prostate. This could lead to a patient being undertreated, which could have serious consequences later on if the cancer grows. The authors believe that relying on just one biopsy to decide on treatment is a flawed approach.
According to a 2022 review published in the Urological Research Society, the lowest grade of prostate cancer, called ISUP Grade Group 1 (GG1), grows very slowly. Because it is so harmless, some experts have suggested that we should stop calling it "cancer" at all. This has been done before for similar low-risk tumors in the bladder and thyroid.
The review summarized that even though GG1 tumors have some characteristics of cancer, their behavior is much more like a harmless, non-cancerous growth. The authors suggest that renaming GG1 prostate cancer could have several benefits:
Challenging the view of previous studies, researchers sought to get a clearer understanding. To get a more accurate picture, the research team looked at data from over 300,000 men. Among those who were initially diagnosed with GG1 tumors, the team used additional factors like PSA levels and tumor size, which can be better indicators of risk.
By combining all this information, they found that a significant number of men—more than 18,000—were actually at higher risk and should have received more aggressive treatment like radiation or surgery. This data strongly suggests that as many as 30% of GG1 diagnoses might be underestimated, leaving many men without the full treatment they need.
The authors of the study are urging doctors to reconsider how they evaluate GG1 tumors. They emphasize that a "low grade" diagnosis from a biopsy isn't the same as a guaranteed "low risk" for the patient. They believe it's a doctor's responsibility to use all available data to accurately assess a man's individual risk. The goal is to ensure that those who need treatment get it, while still safely recommending active surveillance for the men who are truly at low risk.
© 2024 Bennett, Coleman & Company Limited